Literature DB >> 8173377

Superficial bladder cancer.

R R Hall1.   

Abstract

Bladder cancer is almost certainly a product of the industrial revolution and the cigarette smoking that has accompanied it. Exposure to a chemical bladder carcinogen such as beta naphthylamine, benzidine, or 4-diphenylaniline can be proved in only a small proportion of patients and only a handful obtain industrial diseases benefit after developing "Prescribed Industrial Disease C23." None the less, the continued use of known carcinogenic substances in British industry for many years after their identification, the wide range of industries with a known or suspected increased risk of bladder cancer, and our ignorance of the carcinogenic potential of many materials used in current manufacturing should be a cause for continuing concern.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8173377      PMCID: PMC2539828          DOI: 10.1136/bmj.308.6933.910

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  19 in total

Review 1.  Molecular analysis of human bladder cancer.

Authors:  A F Olumi; E C Skinner; Y C Tsai; P A Jones
Journal:  Semin Urol       Date:  1990-11

2.  From gene to carcinogen: a rapidly evolving field in molecular epidemiology.

Authors:  P A Jones; J D Buckley; B E Henderson; R K Ross; M C Pike
Journal:  Cancer Res       Date:  1991-07-01       Impact factor: 12.701

3.  Should pT1 transitional cell cancers of the bladder still be classified as superficial?

Authors:  P D Abel; R R Hall; G Williams
Journal:  Br J Urol       Date:  1988-09

4.  Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).

Authors:  M K Parmar; L S Freedman; T B Hargreave; D A Tolley
Journal:  J Urol       Date:  1989-08       Impact factor: 7.450

5.  Cigarette smoking and bladder cancer.

Authors:  B D'Avanzo; E Negri; C La Vecchia; A Gramenzi; C Bianchi; S Franceschi; P Boyle
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

6.  A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.

Authors:  D L Lamm; B A Blumenstein; E D Crawford; J E Montie; P Scardino; H B Grossman; T H Stanisic; J A Smith; J Sullivan; M F Sarosdy
Journal:  N Engl J Med       Date:  1991-10-24       Impact factor: 91.245

7.  Familial aggregation of bladder cancer stratified by smoking status.

Authors:  A A Kramer; S Graham; W S Burnett; P Nasca
Journal:  Epidemiology       Date:  1991-03       Impact factor: 4.822

8.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

9.  The possible influence of antibiotics on results of bacillus Calmette-Guérin intravesical therapy for superficial bladder cancer.

Authors:  P M van der Meijden; B van Klingeren; P A Steerenberg; L C de Boer; W H de Jong; F M Debruyne
Journal:  J Urol       Date:  1991-08       Impact factor: 7.450

10.  Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder.

Authors:  C Wright; K Mellon; P Johnston; D P Lane; A L Harris; C H Horne; D E Neal
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.